在患有早期急性至慢性肝衰竭的患者中治疗肝综合征的terlipressin
Don C Rockey1, Fredric Gordon2, Paul J Thuluvath3
1Digestive Disease Research Center, Medical University of South Carolina, Charleston, South Carolina, USA.
概括
在精选的患者中,特里普林素有效治疗肝综合征-急性损伤 (HRS-AKI). 这项分析发现,在没有严重肝脏或脏功能障碍的HRS-AKI患者中,没有增加呼吸衰竭风险的改善结果.
科学领域:
- 胃肠病学和肝病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临床药理学 临床药理学
背景情况:
- 肝综合征-急性损伤 (HRS-AKI) 是不补偿性肝硬化症的严重并发症.
- 特里普林被FDA批准用于HRS-AKI,但存在关于呼吸衰竭和晚期疾病有效性有限的担忧.
- 在CONFIRM研究中确定了terlipressin的疗效,标签上针对ACLF等级3或SCr ≥5 mg/dL的特殊警告.
研究的目的:
- 评估特里普林素在HRS-AKI患者的疗效和安全性,具有更有利的益处与风险概况.
- 评估特里普林素对临床结果的影响,不包括患有ACLF 3级或SCr ≥5 mg/dL的患者.
主要方法:
- 对CONFIRM研究数据的后期分析.
- 排除患有急性转慢性肝衰竭 (ACLF) 3级或血清肌素 (SCr) ≥5 mg/dL的患者.
- 评估有效性结局,包括HRS逆转,替代疗法 (RRT),肝移植 (LT) 和存活率,以及SCr,MELD和血清的变化.
主要成果:
- 特里普林素显著改善了HRS逆转 (43%与17%的安慰剂相比,p<0.001).
- 与安慰剂相比,terlipressin导致SCr的较大降低和血清的增加 (p < 0.001).
- 在terlipressin和安慰剂组之间,呼吸衰竭发生率相似 (11%对7%,p=0.360),这表明在这个选定人群中安全性概况有利.
结论:
- 在没有基线ACLF 3级或SCr ≥5 mg/dL的HRS-AKI患者中,特里普林素显示出改善的临床结果.
- 在这个选择的队列中,terlipressin治疗与呼吸衰竭的风险增加无关.
- 这些发现支持在精心挑选的HRS-AKI群体中使用terlipressin,以获得更好的治疗效益.
相关概念视频
01:30Continuous Renal Replacement Therapy
783
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
783
01:20Acute Kidney Injury V: Interprofessional Care
287
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
287
01:11Renal Failure: Dose Adjustments
416
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
416
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:22Acute Kidney Injury VI: Nursing Management
373
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
373
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
428
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
428